Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review.

about

Systems Pharmacology Model of Gastrointestinal Damage Predicts Species Differences and Optimizes Clinical Dosing Schedules.

P2860

Q46302099-869FB500-24BD-49A5-935C-03C7A1E6D9F7

P2860

Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review.

Item

http://www.wikidata.org/entity/Q38673003

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Decreased gastrointestinal tox ...... ays off): a systematic review.

@en

type

Item

label

Decreased gastrointestinal tox ...... ays off): a systematic review.

@en

prefLabel

Decreased gastrointestinal tox ...... ays off): a systematic review.

@en

P1476

Decreased gastrointestinal tox ...... ays off): a systematic review.

@en

P2093

Clifford A Hudis

http://www.w3.org/2001/XMLSchema#string

Devika Gajria

http://www.w3.org/2001/XMLSchema#string

Emily Suh

http://www.w3.org/2001/XMLSchema#string

Karen A Cadoo

http://www.w3.org/2001/XMLSchema#string

Maria Theodoulou

http://www.w3.org/2001/XMLSchema#string

Sujata Patil

http://www.w3.org/2001/XMLSchema#string

Tiffany A Traina

http://www.w3.org/2001/XMLSchema#string

P2860

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling.

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.

Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.

Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?

P2888

npjbcancer.2016.6

P304

16006

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NPJBCANCER.2016.6

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Larry Norton

P577

2016-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1050999294

http://www.w3.org/2001/XMLSchema#string

P698

28721374

http://www.w3.org/2001/XMLSchema#string

P932

5515341

http://www.w3.org/2001/XMLSchema#string

Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review.

about

P2860

P2860

Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P6179

P698

P932